Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1382879,Cmax,"The area under curve was 48% greater (P less than 0.01) and Cmax was higher in Group 2 than in Group 1, 145.8 +/- 42.2 vs 107 +/- 20.5 ng.",Clinical and pharmacokinetic aspects of the combination of meperidine and prilocaine for spinal anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1382879/),ng,145.8,29976,DB00750,Prilocaine
,1382879,Cmax,"The area under curve was 48% greater (P less than 0.01) and Cmax was higher in Group 2 than in Group 1, 145.8 +/- 42.2 vs 107 +/- 20.5 ng.",Clinical and pharmacokinetic aspects of the combination of meperidine and prilocaine for spinal anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1382879/),ng,107,29977,DB00750,Prilocaine
,2389069,maximum levels,"Plasma concentrations after 200 (n = 12) and 300 mg prilocaine (n = 3) peaked between 10 and 20 min after cuff release, respectively, with maximum levels of 0.96 micrograms/ml (means = 0.56 micrograms/ml) and 1.45 micrograms/ml.","[Intravenous regional anesthesia of the foot using prilocaine. Clinical aspects, pharmacokinetic and pharmacodynamic studies]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389069/),[μg] / [ml],0.96,37916,DB00750,Prilocaine
,2389069,maximum levels,"Plasma concentrations after 200 (n = 12) and 300 mg prilocaine (n = 3) peaked between 10 and 20 min after cuff release, respectively, with maximum levels of 0.96 micrograms/ml (means = 0.56 micrograms/ml) and 1.45 micrograms/ml.","[Intravenous regional anesthesia of the foot using prilocaine. Clinical aspects, pharmacokinetic and pharmacodynamic studies]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389069/),[μg] / [ml],0.56,37917,DB00750,Prilocaine
,2389069,maximum levels,"Plasma concentrations after 200 (n = 12) and 300 mg prilocaine (n = 3) peaked between 10 and 20 min after cuff release, respectively, with maximum levels of 0.96 micrograms/ml (means = 0.56 micrograms/ml) and 1.45 micrograms/ml.","[Intravenous regional anesthesia of the foot using prilocaine. Clinical aspects, pharmacokinetic and pharmacodynamic studies]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389069/),[μg] / [ml],1.45,37918,DB00750,Prilocaine
,9010944,onset time of sensory block,"The onset time of sensory block was significantly shorter (2.5 minutes) in the articaine group than in the lidocaine group (11.1 minutes) or the prilocaine group (10.9 minutes) (Scheffe, P < .05).","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),min,2.5,62083,DB00750,Prilocaine
,9010944,onset time of sensory block,"The onset time of sensory block was significantly shorter (2.5 minutes) in the articaine group than in the lidocaine group (11.1 minutes) or the prilocaine group (10.9 minutes) (Scheffe, P < .05).","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),min,11.1,62084,DB00750,Prilocaine
,9010944,onset time of sensory block,"The onset time of sensory block was significantly shorter (2.5 minutes) in the articaine group than in the lidocaine group (11.1 minutes) or the prilocaine group (10.9 minutes) (Scheffe, P < .05).","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),min,10.9,62085,DB00750,Prilocaine
,9010944,Maximum concentrations,"Maximum concentrations of articaine, lidocaine, and prilocaine were, 1.85, 8.5, and 4.4 micrograms/mL, respectively.","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),[μg] / [ml],1.85,62086,DB00750,Prilocaine
,9010944,Maximum concentrations,"Maximum concentrations of articaine, lidocaine, and prilocaine were, 1.85, 8.5, and 4.4 micrograms/mL, respectively.","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),[μg] / [ml],8.5,62087,DB00750,Prilocaine
,9010944,Maximum concentrations,"Maximum concentrations of articaine, lidocaine, and prilocaine were, 1.85, 8.5, and 4.4 micrograms/mL, respectively.","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),[μg] / [ml],4.4,62088,DB00750,Prilocaine
,30811630,Cmax,"Mean values of Cmax were 14.20 and 5.36 ng/ml and tmax were 3.5 and 1.8 hour for lidocaine and prilocaine, respectively.","Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811630/),[ng] / [ml],14.20,65603,DB00750,Prilocaine
,30811630,Cmax,"Mean values of Cmax were 14.20 and 5.36 ng/ml and tmax were 3.5 and 1.8 hour for lidocaine and prilocaine, respectively.","Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811630/),[ng] / [ml],5.36,65604,DB00750,Prilocaine
,30811630,tmax,"Mean values of Cmax were 14.20 and 5.36 ng/ml and tmax were 3.5 and 1.8 hour for lidocaine and prilocaine, respectively.","Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811630/),h,3.5,65605,DB00750,Prilocaine
,30811630,tmax,"Mean values of Cmax were 14.20 and 5.36 ng/ml and tmax were 3.5 and 1.8 hour for lidocaine and prilocaine, respectively.","Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811630/),h,1.8,65606,DB00750,Prilocaine
,2287764,Maximal prilocaine serum levels,Maximal prilocaine serum levels of 2.32 +/- 0.80 micrograms/ml were found after 34 +/- 13 min.,[The blood level and a pharmacokinetic model of prilocaine during a continuous brachial plexus blockade]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287764/),[μg] / [ml],2.32,70316,DB00750,Prilocaine
,2287764,t alpha 1/2,Mean pharmacokinetic data of the open two-compartment model with first order absorption from extravascular sites were: t alpha 1/2 = 10 min; t beta 1/2 = 139 min; V1 = 661; V dss = 254 1; Cltot = 2310 ml/min; tabs 1/2 = 35 min.,[The blood level and a pharmacokinetic model of prilocaine during a continuous brachial plexus blockade]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287764/),min,10,70317,DB00750,Prilocaine
,2287764,t beta 1/2,Mean pharmacokinetic data of the open two-compartment model with first order absorption from extravascular sites were: t alpha 1/2 = 10 min; t beta 1/2 = 139 min; V1 = 661; V dss = 254 1; Cltot = 2310 ml/min; tabs 1/2 = 35 min.,[The blood level and a pharmacokinetic model of prilocaine during a continuous brachial plexus blockade]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287764/),min,139,70318,DB00750,Prilocaine
,2287764,V1,Mean pharmacokinetic data of the open two-compartment model with first order absorption from extravascular sites were: t alpha 1/2 = 10 min; t beta 1/2 = 139 min; V1 = 661; V dss = 254 1; Cltot = 2310 ml/min; tabs 1/2 = 35 min.,[The blood level and a pharmacokinetic model of prilocaine during a continuous brachial plexus blockade]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287764/),,661,70319,DB00750,Prilocaine
,2287764,V dss,Mean pharmacokinetic data of the open two-compartment model with first order absorption from extravascular sites were: t alpha 1/2 = 10 min; t beta 1/2 = 139 min; V1 = 661; V dss = 254 1; Cltot = 2310 ml/min; tabs 1/2 = 35 min.,[The blood level and a pharmacokinetic model of prilocaine during a continuous brachial plexus blockade]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287764/),1,254,70320,DB00750,Prilocaine
,2287764,Cltot,Mean pharmacokinetic data of the open two-compartment model with first order absorption from extravascular sites were: t alpha 1/2 = 10 min; t beta 1/2 = 139 min; V1 = 661; V dss = 254 1; Cltot = 2310 ml/min; tabs 1/2 = 35 min.,[The blood level and a pharmacokinetic model of prilocaine during a continuous brachial plexus blockade]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287764/),[ml] / [min],2310,70321,DB00750,Prilocaine
,2287764,tabs 1/2,Mean pharmacokinetic data of the open two-compartment model with first order absorption from extravascular sites were: t alpha 1/2 = 10 min; t beta 1/2 = 139 min; V1 = 661; V dss = 254 1; Cltot = 2310 ml/min; tabs 1/2 = 35 min.,[The blood level and a pharmacokinetic model of prilocaine during a continuous brachial plexus blockade]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287764/),min,35,70322,DB00750,Prilocaine
,1441871,maximum venous plasma concentrations,The mean maximum venous plasma concentrations of mepivacaine were more than twice as high as when prilocaine was used as anaesthetic (5.1 micrograms/ml vs. 2.37 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],5.1,79761,DB00750,Prilocaine
,1441871,maximum venous plasma concentrations,The mean maximum venous plasma concentrations of mepivacaine were more than twice as high as when prilocaine was used as anaesthetic (5.1 micrograms/ml vs. 2.37 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],2.37,79762,DB00750,Prilocaine
exceeded,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],5,79763,DB00750,Prilocaine
,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[mg] / [ml],7.21,79764,DB00750,Prilocaine
,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],8.61,79765,DB00750,Prilocaine
,1441871,maximum,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[mg] / [ml],7.21,79766,DB00750,Prilocaine
,1441871,maximum,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],8.61,79767,DB00750,Prilocaine
,10486075,half-life,Pharmacokinetic evaluation indicated a single compartment first-order elimination with a methaemoglobin half-life of 8 h.,Toxic methaemoglobin concentrations in premature infants after application of a prilocaine-containing cream and peridural prilocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10486075/),h,8,87924,DB00750,Prilocaine
,9481979,maximum concentration,"The maximum concentration measured in any subject was 418 ng/ml for lidocaine and 223 ng/ml for prilocaine, well below known toxic levels.",Pharmacokinetics of EMLA cream 5% application to oral mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9481979/),[ng] / [ml],418,89258,DB00750,Prilocaine
,9481979,maximum concentration,"The maximum concentration measured in any subject was 418 ng/ml for lidocaine and 223 ng/ml for prilocaine, well below known toxic levels.",Pharmacokinetics of EMLA cream 5% application to oral mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9481979/),[ng] / [ml],223,89259,DB00750,Prilocaine
,11403247,oxygen saturation,Mean oxygen saturation was 98.9 +/- 0.01%.,Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11403247/),%,98.9,107650,DB00750,Prilocaine
,4053490,serum peak,"On the contrary, prilocaine resorption by the synovium was fast and induced a sharp serum peak (265.8 +/- 163.5 ng/ml) in the hour after the end of the examination.",Prilocaine in arthroscopy: clinical pharmacokinetics and rational use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053490/),[ng] / [ml],265.8,111342,DB00750,Prilocaine
,4053490,t1/2,"The drug was completely eliminated from the blood after 24 hours, as the prilocaine t1/2 is about 5 hours.",Prilocaine in arthroscopy: clinical pharmacokinetics and rational use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053490/),h,5,111343,DB00750,Prilocaine
,19954712,Cmax,Mean prilocaine peak plasma concentrations (mean Cmax = 1.51 microg/ml) were measured between 15 and 30 min after injection.,Pharmacokinetics and clinical toxicity of prilocaine and ropivacaine following combined drug administration in brachial plexus anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954712/),[μg] / [ml],1.51,164463,DB00750,Prilocaine
,19954712,Cmax,Highest ropivacaine plasma concentrations (mean Cmax = 1.12 microg/ml) were seen between 30 min and 1 hour after injection (calculated mean tmax = 44 min).,Pharmacokinetics and clinical toxicity of prilocaine and ropivacaine following combined drug administration in brachial plexus anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954712/),[μg] / [ml],1.12,164464,DB00750,Prilocaine
,19954712,tmax,Highest ropivacaine plasma concentrations (mean Cmax = 1.12 microg/ml) were seen between 30 min and 1 hour after injection (calculated mean tmax = 44 min).,Pharmacokinetics and clinical toxicity of prilocaine and ropivacaine following combined drug administration in brachial plexus anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954712/),min,44,164465,DB00750,Prilocaine
,9373813,onset time,The mean onset time of surgical analgesia of lidocaine was 11.2 +/- 5.1 min and that of prilocaine was 10.9 +/- 6.0 min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,11.2,164808,DB00750,Prilocaine
,9373813,onset time,The mean onset time of surgical analgesia of lidocaine was 11.2 +/- 5.1 min and that of prilocaine was 10.9 +/- 6.0 min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,10.9,164809,DB00750,Prilocaine
,9373813,t1/2 alpha,"After releasing the tourniquet, lidocaine is bi-exponentially eliminated with a t1/2 alpha of 4.3 +/- 2.1 min and a t1/2 beta of 79.1 +/- 31.2 min.",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,4.3,164810,DB00750,Prilocaine
,9373813,t1/2 beta,"After releasing the tourniquet, lidocaine is bi-exponentially eliminated with a t1/2 alpha of 4.3 +/- 2.1 min and a t1/2 beta of 79.1 +/- 31.2 min.",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,79.1,164811,DB00750,Prilocaine
,9373813,Total body clearance,Total body clearance was 0.86 +/- 0.39 litres/min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),[l] / [min],0.86,164812,DB00750,Prilocaine
,9373813,t1/2 alpha,Prilocaine is rapidly and bi-exponentially eliminated with a t1/2 alpha of 3.0 +/- 1.6 min and a t1/2 beta of 29.9 +/- 15.7 min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,3.0,164813,DB00750,Prilocaine
,9373813,t1/2 beta,Prilocaine is rapidly and bi-exponentially eliminated with a t1/2 alpha of 3.0 +/- 1.6 min and a t1/2 beta of 29.9 +/- 15.7 min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,29.9,164814,DB00750,Prilocaine
,9373813,total body clearance,"The total body clearance of prilocaine is higher than that of lidocaine, 4.15 +/- 1.31 vs.",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),,4.15,164815,DB00750,Prilocaine
,9373813,t1/2 alpha,"Both compounds show comparable volumes of distribution (Vd, Vss and V beta) and a comparable t1/2 alpha (4.3 +/- 2.1 vs. 3.0 +/- 1.6 min; P = 0.1780).",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,4.3,164816,DB00750,Prilocaine
,9373813,t1/2 alpha,"Both compounds show comparable volumes of distribution (Vd, Vss and V beta) and a comparable t1/2 alpha (4.3 +/- 2.1 vs. 3.0 +/- 1.6 min; P = 0.1780).",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,3.0,164817,DB00750,Prilocaine
,9373813,t1/2 beta,The t1/2 beta for the two compounds were different (P = 0031); 79.1 +/- 31.2 min for lidocaine and 29.9 +/- 15.7 min for prilocaine.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,79.1,164818,DB00750,Prilocaine
,9373813,t1/2 beta,The t1/2 beta for the two compounds were different (P = 0031); 79.1 +/- 31.2 min for lidocaine and 29.9 +/- 15.7 min for prilocaine.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,29.9,164819,DB00750,Prilocaine
,9373813,mean residence time (MRT),The mean residence time (MRT) of lidocaine (193 +/- 233 min) also differed significantly from that of prilocaine (33.4 +/- 19.9 min; P = 0.0022).,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,193,164820,DB00750,Prilocaine
,9373813,mean residence time (MRT),The mean residence time (MRT) of lidocaine (193 +/- 233 min) also differed significantly from that of prilocaine (33.4 +/- 19.9 min; P = 0.0022).,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,33.4,164821,DB00750,Prilocaine
,18370545,onset time,The mean onset time of surgical analgesia of both lidocaine and prilocaine was 10 minutes.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,10,167805,DB00750,Prilocaine
,18370545,elimination phase half-life (t((1/2)alpha)),Lidocaine was biexponentially eliminated with a rapid elimination phase half-life (t((1/2)alpha)) of 9.95 +/- 14.3 minutes and a terminal elimination phase half-life (t((1/2)beta)) of 2.86 +/- 1.55 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,9.95,167806,DB00750,Prilocaine
,18370545,terminal elimination phase half-life (t((1/2)beta)),Lidocaine was biexponentially eliminated with a rapid elimination phase half-life (t((1/2)alpha)) of 9.95 +/- 14.3 minutes and a terminal elimination phase half-life (t((1/2)beta)) of 2.86 +/- 1.55 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.86,167807,DB00750,Prilocaine
,18370545,time to reach maximum plasma concentration (tmax),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.3,167808,DB00750,Prilocaine
,18370545,maximum plasma concentration (C(max)),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[mg] / [l],0.32,167809,DB00750,Prilocaine
,18370545,t((1/2)beta),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.4,167810,DB00750,Prilocaine
,18370545,total body clearance,Lidocaine total body clearance was 67.8 +/- 28.8 L/h.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[l] / [h],67.8,167811,DB00750,Prilocaine
,18370545,t((1/2)alpha),Prilocaine was rapidly and biexponentially eliminated with a t((1/2)alpha) of 9.4 +/- 18.4 minutes and a t((1/2)beta) of 2.12 +/- 1.28 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,9.4,167812,DB00750,Prilocaine
,18370545,t((1/2)beta),Prilocaine was rapidly and biexponentially eliminated with a t((1/2)alpha) of 9.4 +/- 18.4 minutes and a t((1/2)beta) of 2.12 +/- 1.28 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.12,167813,DB00750,Prilocaine
,18370545,total body clearance,The total body clearance of prilocaine (150 +/- 53 L/h) was higher than that of lidocaine (p = 0.0255).,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[l] / [h],150,167814,DB00750,Prilocaine
,25525759,run-time,"The chromatography run-time was 5.5 minutes for lidocaine and 3.3 minutes for prilocaine, and the lower limit of quantification was 0.05 ng/mL for both drugs.",Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),min,5.5,184169,DB00750,Prilocaine
,25525759,run-time,"The chromatography run-time was 5.5 minutes for lidocaine and 3.3 minutes for prilocaine, and the lower limit of quantification was 0.05 ng/mL for both drugs.",Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),min,3.3,184170,DB00750,Prilocaine
,25525759,Cmax,"Mean Cmax was 6.62 and 1.72 ng/mL for lidocaine and prilocaine, respectively.",Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),[ng] / [ml],6.62,184171,DB00750,Prilocaine
,25525759,Cmax,"Mean Cmax was 6.62 and 1.72 ng/mL for lidocaine and prilocaine, respectively.",Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),[ng] / [ml],1.72,184172,DB00750,Prilocaine
,25525759,Tmax,Median Tmax was 6.5 hours for both drugs.,Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),h,6.5,184173,DB00750,Prilocaine
,14706243,relative in vivo recoveries,The relative in vivo recoveries in striatum (11.3%) and blood (24.0%) were significantly lower than in vitro (31.3 and 44.9%).,A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,11.3,192565,DB00750,Prilocaine
,14706243,relative in vivo recoveries,The relative in vivo recoveries in striatum (11.3%) and blood (24.0%) were significantly lower than in vitro (31.3 and 44.9%).,A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,24.0,192566,DB00750,Prilocaine
,14706243,relative in vivo recoveries,The relative in vivo recoveries in striatum (11.3%) and blood (24.0%) were significantly lower than in vitro (31.3 and 44.9%).,A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,31.3,192567,DB00750,Prilocaine
,14706243,relative in vivo recoveries,The relative in vivo recoveries in striatum (11.3%) and blood (24.0%) were significantly lower than in vitro (31.3 and 44.9%).,A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,44.9,192568,DB00750,Prilocaine
,14706243,nasal bioavailabilities,"The average nasal bioavailabilities of lidocaine in blood, left and right striatum were 85, 103 and 129%, respectively.",A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,85,192569,DB00750,Prilocaine
,14706243,nasal bioavailabilities,"The average nasal bioavailabilities of lidocaine in blood, left and right striatum were 85, 103 and 129%, respectively.",A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,103,192570,DB00750,Prilocaine
,14706243,nasal bioavailabilities,"The average nasal bioavailabilities of lidocaine in blood, left and right striatum were 85, 103 and 129%, respectively.",A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,129,192571,DB00750,Prilocaine
,15966499,half-lives of elimination (t1/2alpha,"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,0.6,192815,DB00750,Prilocaine
,15966499,t1/2beta),"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,2.5,192816,DB00750,Prilocaine
,15966499,apparent half-life,"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,2.5,192817,DB00750,Prilocaine
,15966499,t1/2alpha,"Intrinsic half-lives of articainic acid are: t1/2alpha 12 minutes, and t1/2beta 64 minutes (1 hour).",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),min,12,192818,DB00750,Prilocaine
,15966499,t1/2beta,"Intrinsic half-lives of articainic acid are: t1/2alpha 12 minutes, and t1/2beta 64 minutes (1 hour).",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),min,64,192819,DB00750,Prilocaine
,17583875,analytical recovery,"The analytical recovery of prilocaine HCl and IS from plasma has averaged 94.79 and 96.8%, respectively.",Development and validation of gas chromatography-mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583875/),%,94.79,205244,DB00750,Prilocaine
,17583875,analytical recovery,"The analytical recovery of prilocaine HCl and IS from plasma has averaged 94.79 and 96.8%, respectively.",Development and validation of gas chromatography-mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583875/),%,96.8,205245,DB00750,Prilocaine
,17583875,LOQ,"LOQ and LOD values for plasma were found to be 20 and 10 ng/mL, respectively.",Development and validation of gas chromatography-mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583875/),[ng] / [ml],20,205246,DB00750,Prilocaine
,17583875,LOD,"LOQ and LOD values for plasma were found to be 20 and 10 ng/mL, respectively.",Development and validation of gas chromatography-mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583875/),[ng] / [ml],10,205247,DB00750,Prilocaine
,3406467,peak prilocaine concentrations,Remarkable differences in peak prilocaine concentrations (64 micrograms/ml vs 7.9 micrograms/ml after the 1st min) were found during the 3-h study period.,[Behavior of plasma concentrations of prilocaine following intravenous regional anesthesia and their relation to methemoglobinemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3406467/),[μg] / [ml],64,212541,DB00750,Prilocaine
,3406467,peak prilocaine concentrations,Remarkable differences in peak prilocaine concentrations (64 micrograms/ml vs 7.9 micrograms/ml after the 1st min) were found during the 3-h study period.,[Behavior of plasma concentrations of prilocaine following intravenous regional anesthesia and their relation to methemoglobinemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3406467/),[μg] / [ml],7.9,212542,DB00750,Prilocaine
,11442278,absorption coefficient,The microemulsion formulations were shown to increase the absorption coefficient of lidocaine more than eight times (753 microg/l/min) compared with a conventional oil-in-water emulsion-based cream (89 microg/l/min) and prilocaine hydrochloride almost two times (8.9 microg/l/min) compared with hydrogel (5.2 microg/l/min).,Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442278/),[μg] / [l·min],753,248532,DB00750,Prilocaine
,11442278,absorption coefficient,The microemulsion formulations were shown to increase the absorption coefficient of lidocaine more than eight times (753 microg/l/min) compared with a conventional oil-in-water emulsion-based cream (89 microg/l/min) and prilocaine hydrochloride almost two times (8.9 microg/l/min) compared with hydrogel (5.2 microg/l/min).,Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442278/),[μg] / [l·min],89,248533,DB00750,Prilocaine
,11442278,absorption coefficient,The microemulsion formulations were shown to increase the absorption coefficient of lidocaine more than eight times (753 microg/l/min) compared with a conventional oil-in-water emulsion-based cream (89 microg/l/min) and prilocaine hydrochloride almost two times (8.9 microg/l/min) compared with hydrogel (5.2 microg/l/min).,Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442278/),[μg] / [l·min],8.9,248534,DB00750,Prilocaine
,11442278,absorption coefficient,The microemulsion formulations were shown to increase the absorption coefficient of lidocaine more than eight times (753 microg/l/min) compared with a conventional oil-in-water emulsion-based cream (89 microg/l/min) and prilocaine hydrochloride almost two times (8.9 microg/l/min) compared with hydrogel (5.2 microg/l/min).,Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442278/),[μg] / [l·min],5.2,248535,DB00750,Prilocaine
,31414038,flow rate,"The reconstituted samples were chromatographed on Phenomenex Kinetex EVO 4.6*100 mm 2.6 μ 100A column by using a mixture of acetonitrile and 5 mM ammonium acetate buffer (80:20, v/v) as the mobile phase at a flow rate of 0.6 mL/min.",Simultaneous quantification of lidocaine and prilocaine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31414038/),[ml] / [min],0.6,265647,DB00750,Prilocaine
,31414038,run time,"A run time of 3.0 min for each sample, make it possible to analyze more than 350 human plasma samples per day.",Simultaneous quantification of lidocaine and prilocaine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31414038/),min,3.0,265648,DB00750,Prilocaine
,29800738,encapsulation efficiency,"The encapsulation efficiency, determined by both direct and indirect methods, was around 36-38%.","Improving the therapeutic efficacy of prilocaine by PLGA microparticles: Preparation, characterization and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29800738/),%,36-38,268144,DB00750,Prilocaine
,10201668,unbound fraction,"The unbound fraction of R(-)-prilocaine (mean +/- SD, 70%+/-8%) was smaller (P < 0.05) than that of S(+)-prilocaine (73%+/-5%).",Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),%,70,269621,DB00750,Prilocaine
,10201668,unbound fraction,"The unbound fraction of R(-)-prilocaine (mean +/- SD, 70%+/-8%) was smaller (P < 0.05) than that of S(+)-prilocaine (73%+/-5%).",Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),%,73,269622,DB00750,Prilocaine
,10201668,total plasma clearance,The total plasma clearance of R(-)-prilocaine (2.57+/-0.46 l/min) was larger (P < 0.0001) than that of S(+)-prilocaine (1.91+/-0.30 l/min).,Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),[l] / [min],2.57,269623,DB00750,Prilocaine
,10201668,total plasma clearance,The total plasma clearance of R(-)-prilocaine (2.57+/-0.46 l/min) was larger (P < 0.0001) than that of S(+)-prilocaine (1.91+/-0.30 l/min).,Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),[l] / [min],1.91,269624,DB00750,Prilocaine
,10201668,steady-state volume of distribution,The steady-state volume of distribution of R(-)-prilocaine (279+/-94 l) did not differ from that of S(+)-prilocaine (291+/-93 l).,Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),l,279,269625,DB00750,Prilocaine
,10201668,steady-state volume of distribution,The steady-state volume of distribution of R(-)-prilocaine (279+/-94 l) did not differ from that of S(+)-prilocaine (291+/-93 l).,Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),l,291,269626,DB00750,Prilocaine
,10201668,terminal half-life,"The terminal half-life of R(-)-prilocaine (87+/-27 min) was shorter (P < 0.05) than that of S(+)-prilocaine (124+/-64 min), as was the mean residence time of R(-)-prilocaine (108+/-30 min) compared with S(+)-prilocaine (155+/-59 min; P < 0.005).",Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),min,87,269627,DB00750,Prilocaine
,10201668,terminal half-life,"The terminal half-life of R(-)-prilocaine (87+/-27 min) was shorter (P < 0.05) than that of S(+)-prilocaine (124+/-64 min), as was the mean residence time of R(-)-prilocaine (108+/-30 min) compared with S(+)-prilocaine (155+/-59 min; P < 0.005).",Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),min,124,269628,DB00750,Prilocaine
,10201668,mean residence time,"The terminal half-life of R(-)-prilocaine (87+/-27 min) was shorter (P < 0.05) than that of S(+)-prilocaine (124+/-64 min), as was the mean residence time of R(-)-prilocaine (108+/-30 min) compared with S(+)-prilocaine (155+/-59 min; P < 0.005).",Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),min,108,269629,DB00750,Prilocaine
,10201668,mean residence time,"The terminal half-life of R(-)-prilocaine (87+/-27 min) was shorter (P < 0.05) than that of S(+)-prilocaine (124+/-64 min), as was the mean residence time of R(-)-prilocaine (108+/-30 min) compared with S(+)-prilocaine (155+/-59 min; P < 0.005).",Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201668/),min,155,269630,DB00750,Prilocaine
